drugset / Trial / NCT06341998
Clinical Study of Chemotherapy in the Treatment of Recurrent/Refractory Yolk Sac Tumor in Children
NaSingle-groupOpen-labelTreatment
Summary
Remarkable progress has been made in treating germ-cell tumor (GCT) through the use of platinum-based regimens. However, part of yolk sac tumor (YST) with cisplatin resistance or recurrence is nevertheless prone to relapse after second-line treatment. This leaves a gap in effective treatment, which needs to be filled by novel therapeutic approaches. This paper is the first one to report the treatment combining sirolimus with nab-paclitaxel, ifosfamide, and carboplatin (S-TIC) for children with repeated relapsed or refractory yolk sac tumor (rrrYST).
Timeline
- Start
- 2020-06-01
- Primary completion
- 2024-01-01
- Completion
- 2024-02-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | 400 mg/m2 | — |
| Subject | Ifosfamide | Small molecule | 1200 mg/m2 | — |
| Subject | Paclitaxel | Small molecule | 200 mg/m2 | — |
| Subject | Sirolimus | Small molecule | 1 mg/m2 | Oral |
| Background | 2-MERCAPTOETHANESULFONIC ACID | Small molecule | — | — |
| Background | Sulfamethoxazole | Small molecule | — | — |